Conversely, patients diagnosed with chronic myeloid leukemia (CML) carrying the OCTN1 rs1050152 variant (p.L503F) had a lower probability of achieving a stable major molecular response to imatinib than the patients expressing wild-type OCTN1 [68]. The gene discussed is SLC22A4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.